Adalimumab, Infliximab and Etanercept Biosimilars Market Growth Outlook Through 2024-2033

Overview and Scope

Adalimumab, infliximab, and etanercept biosimilars refer to a novel class of medications that work to inhibit the effects of the inflammatory mediator tumour necrosis factor-alpha (TNF-alpha). A chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-alpha) is known as an infliximab biosimilar. Immune system disorders are treated with it.

Sizing and Forecast

The adalimumab, infliximab and etanercept biosimilars market size has grown exponentially in recent years. It will grow from $3.67 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives and rising healthcare costs..

The adalimumab, infliximab and etanercept biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.79 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to a rise in healthcare expenditure, aging population and an increase in healthcare access will drive market growth. . Major trends in the forecast period include focus on launching new products, focus on mergers and acquisitions, focus on establishing strategic partnerships and focus on increasing investments..

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Segmentation & Regional Insights

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

North America was the largest region in the adalimumab, infliximab and etanercept biosimilars market in 2023. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Major Driver Impacting Market Growth

The patent expiration of branded drugs allows biosimilars to enter the adalimumab, infliximab, and etanercept biosimilars market. For instance, in the United States, the FDA approved inflectra, developed by Hospira (a Pfizer Inc. company), for the treatment of various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, after the patent expiry of the branded drug Remicade. Similarly, Amgen’s Enbrel had its patent expire in the EU, and with the expiry of the patent, Benepali (a biosimilar of Enbrel) was approved by the European Commission. Humira’s patent expired, and its biosimilars were made available on the market. The FDA has recently (July 2020) approved Hulio, the sixth biosimilar of Humira. Therefore, the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade will drive the adalimumab, infliximab, and etanercept biosimilars market demand.

Key Industry Players

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market report are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Celgene Corporation, AstraZeneca, Merck & Co, Gilead Sciences, Regeneron Pharmaceuticals, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc, Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Ache, Eurofarma, Sanofi, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

The adalimumab, infliximab and etanercept biosimilars market report table of contents includes:

1. Executive Summary

2. Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics

3. Adalimumab, Infliximab and Etanercept Biosimilars Market Trends And Strategies

4. Adalimumab, Infliximab and Etanercept Biosimilars Market – Macro Economic Scenario

5. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size and Growth

…

32. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Benchmarking

33. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market

35. Adalimumab, Infliximab and Etanercept Biosimilars Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model